Laminin 332 expression in breast carcinoma

Soon Young Kwon, Seoung W. Chae, Sharon P. Wilczynski, Ahmad Arain, Philip M. Carpenter

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Laminin 332 (LN332) is a basally expressed extracellular matrix protein that enhances the migration and invasion of breast carcinoma cells. The goal of this study was to examine LN332 expression breast carcinoma. Triple negative breast carcinomas lack estrogen receptor (ER), progesterone receptor (PR) expression and HER2 positivity. Immunohistochemistry for ER, PR, HER2, and dual silver in situ hybridization for the HER2 gene were used to define the phenotype of 243 breast cancers in biopsies or arrays. Immunohistochemistry for LN332 revealed that 70% of triple negative carcinomas stained for LN332. Cytokeratins 5/6 (CK5/6), epidermal growth factor receptor and p63 alone stained fewer triple negative breast carcinomas each, but the combination of LN332 and CK5/6 or epidermal growth factor receptor identified 92% of triple negative breast carcinoma. Of the 163 non-triple negative cases, LN332 was expressed in only 15%. The identification of LN332 in triple negative breast carcinomas is consistent with gene profiling studies showing its expression among breast carcinomas with a basal phenotype. The observation that a proinvasive protein such as LN332 is expressed in breast cancer suggests another mechanism by which the triple negative phenotype could be aggressive.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume20
Issue number2
DOIs
Publication statusPublished - 2012 Mar 1
Externally publishedYes

Keywords

  • basal-like phenotype
  • breast carcinoma
  • HER2 dual in situ hybridization
  • immunohistochemistry
  • laminin 332
  • triple negative

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Laminin 332 expression in breast carcinoma'. Together they form a unique fingerprint.

  • Cite this